Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$668.58 USD

668.58
1,298,850

+5.33 (0.80%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $667.86 -0.72 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Zacks Equity Research

Here's Why Investors Should Retain Myriad Genetics (MYGN) Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.

Zacks Equity Research

Is McKesson (MCK) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Veeva Systems (VEEV) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) Q2 earnings are likely to have been driven by strength in its commercial business.

Zacks Equity Research

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

Zacks Equity Research

Fresenius Medical (FMS) Robust Product Portfolio Drives Growth

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Zacks Equity Research

Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q4 results are likely to have been driven by robust segmental performances.

Zacks Equity Research

3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Zacks Equity Research

Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.

Zacks Equity Research

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Zacks Equity Research

Abbott (ABT) to Offer New Treatment Option for Chronic Pain

by Zacks Equity Research

Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences' (EXAS) better-than-expected results and robust Cologuard volumes.

Zacks Equity Research

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Medtronic (MDT) posts better-than-expected results for the fiscal first quarter and maintains earnings and sales outlook for the full year.

Zacks Equity Research

3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.

Zacks Equity Research

Here's Why You Should Buy McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in McKesson a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.

Zacks Equity Research

Thermo Fisher (TMO) to Offer Wheat & Sesame Allergy Testing

by Zacks Equity Research

Thermo Fisher's (TMO) ImmunoCAP blood tests receive FDA approval for wheat and sesame allergy diagnosis.

Zacks Equity Research

Here's Why You Should Buy ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

Zacks Equity Research

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen's (NXGN) solid product portfolio and continued demand for its solutions raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Hold on to Catalent (CTLT) Stock Now

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Zacks Equity Research

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.